- Home
- KOD vs VXRT Comparison
KOD vs VXRT Comparison
Compare KOD & VXRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KOD
- VXRT
- Stock Information
- Founded
- KOD 2009
- VXRT N/A
- Country
- KOD United States
- VXRT United States
- Employees
- KOD N/A
- VXRT N/A
- Industry
- KOD Biotechnology: Biological Products (No Diagnostic Substances)
- VXRT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KOD Health Care
- VXRT Health Care
- Exchange
- KOD Nasdaq
- VXRT Nasdaq
- Market Cap
- KOD 115.0M
- VXRT 119.0M
- IPO Year
- KOD 2018
- VXRT N/A
- Fundamental
- Price
- KOD $3.77
- VXRT $0.42
- Analyst Decision
- KOD Hold
- VXRT Strong Buy
- Analyst Count
- KOD 3
- VXRT 2
- Target Price
- KOD $9.00
- VXRT $3.00
- AVG Volume (30 Days)
- KOD 468.9K
- VXRT 1.4M
- Earning Date
- KOD 05-19-2025
- VXRT 05-13-2025
- Dividend Yield
- KOD N/A
- VXRT N/A
- EPS Growth
- KOD N/A
- VXRT N/A
- EPS
- KOD N/A
- VXRT N/A
- Revenue
- KOD N/A
- VXRT $28,700,000.00
- Revenue This Year
- KOD N/A
- VXRT N/A
- Revenue Next Year
- KOD N/A
- VXRT N/A
- P/E Ratio
- KOD N/A
- VXRT N/A
- Revenue Growth
- KOD N/A
- VXRT 288.94
- 52 Week Low
- KOD $1.92
- VXRT $0.28
- 52 Week High
- KOD $11.60
- VXRT $1.07
- Technical
- Relative Strength Index (RSI)
- KOD 50.83
- VXRT 52.21
- Support Level
- KOD $3.66
- VXRT $0.37
- Resistance Level
- KOD $4.20
- VXRT $0.38
- Average True Range (ATR)
- KOD 0.49
- VXRT 0.04
- MACD
- KOD 0.00
- VXRT 0.01
- Stochastic Oscillator
- KOD 25.14
- VXRT 59.73
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.
About VXRT Vaxart Inc
Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States.